- Home
- MESO vs BCAT Comparison
MESO vs BCAT Comparison
Compare MESO & BCAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- BCAT
- Stock Information
- Founded
- MESO 2004
- BCAT 2020
- Country
- MESO Australia
- BCAT United States
- Employees
- MESO N/A
- BCAT N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- BCAT Finance/Investors Services
- Sector
- MESO Health Care
- BCAT Finance
- Exchange
- MESO Nasdaq
- BCAT Nasdaq
- Market Cap
- MESO 1.3B
- BCAT 1.5B
- IPO Year
- MESO N/A
- BCAT N/A
- Fundamental
- Price
- MESO $15.17
- BCAT $14.81
- Analyst Decision
- MESO Buy
- BCAT
- Analyst Count
- MESO 4
- BCAT 0
- Target Price
- MESO $18.00
- BCAT N/A
- AVG Volume (30 Days)
- MESO 314.4K
- BCAT 308.8K
- Earning Date
- MESO 08-28-2025
- BCAT 01-01-0001
- Dividend Yield
- MESO N/A
- BCAT 9.38%
- EPS Growth
- MESO N/A
- BCAT N/A
- EPS
- MESO N/A
- BCAT 1.43
- Revenue
- MESO $5,670,000.00
- BCAT N/A
- Revenue This Year
- MESO $177.23
- BCAT N/A
- Revenue Next Year
- MESO $314.04
- BCAT N/A
- P/E Ratio
- MESO N/A
- BCAT $11.41
- Revenue Growth
- MESO N/A
- BCAT N/A
- 52 Week Low
- MESO $5.78
- BCAT $13.67
- 52 Week High
- MESO $22.00
- BCAT $16.38
- Technical
- Relative Strength Index (RSI)
- MESO 60.94
- BCAT 42.42
- Support Level
- MESO $14.45
- BCAT $14.90
- Resistance Level
- MESO $16.23
- BCAT $15.07
- Average True Range (ATR)
- MESO 0.57
- BCAT 0.15
- MACD
- MESO 0.10
- BCAT -0.02
- Stochastic Oscillator
- MESO 63.12
- BCAT 36.59
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
About BCAT BlackRock Capital Allocation Term Trust of Beneficial Interest
BlackRock Capital Allocation Trust is a non-diversified, closed-end management investment company. The investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation.